Transgenic plant-derived pharmaceuticals - The practical approach?

Expert Opinion on Biological Therapy

Volumn 4, Issue 10, 2004, Pages 1565-1568

  Yano, Akira ^a   Takekoshi, Masataka ^b  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibody; Biopharmaceutical; Developing country; GM crop; Transgenic plant

Indexed keywords

ANTIBODY;

AGRICULTURE; BIOTECHNOLOGY; CLIMATE CHANGE; CONTAMINATION; DERIVATIZATION; DEVELOPING COUNTRY; DRUG INDUSTRY; GENETICALLY MODIFIED CROP; HUMAN GENOME; NONHUMAN; RECOMBINANT DNA TECHNOLOGY; RELIABILITY; REVIEW; RISK BENEFIT ANALYSIS; SUSTAINABLE DEVELOPMENT; TRANSGENIC PLANT;

ANIMALS; ANTIBODIES, MONOCLONAL; DNA, RECOMBINANT; DRUG CONTAMINATION; DRUG DESIGN; GENETIC ENGINEERING; HUMANS; PHARMACEUTICAL PREPARATIONS; PLANTS, GENETICALLY MODIFIED; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; SAFETY; TECHNOLOGY, PHARMACEUTICAL;

EID: 5644302317     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.10.1565     Document Type: Review

References (29)

1. LANDER ES, LINTON LM, BIRREN B et al.: Initial sequencing analysis of the human genome. Nature (2001) 409(6822):860-921.
2. ABUIN A, HOLT KH, PLATT KA, SANDS AT, ZAMBROWICZ BP: Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol. (2002) 20(1):36-42.
3. SIMOENS C, VAN MONTAGU M: Genetic engineering in plants. Hum. Reprod. Update (1995) 1(6):525-542.
4. THE ROYAL SOCIETY OF LONDON et al.: Transgenic Plants and World Agriculture. National Academy Press, Washington DC, USA (2000):1-40. Important report under the auspices of the international science societies. Can be accessed at http://books.nap.edu/html/transgenic/
5. VASIL IK: The science and politics of plant biotechnology - a personal perspective. Nat. Biotechnology. (2003) 21(8):849-851.
6. FISCHER R, TWYMAN RM, SCHILLBERG S: Production of antibodies in plants and their use for global health. Vaccine (2003) 21(7-8):820-825.
7. GARBER K: Biotech industry faces new bottleneck Nat. Biotechnol. (2001) 19(3):184-185.
8. BAKKER H, BARDOR M, MOLTHOFF JW et al.: Galactose-extended glycans of antibodies produced by transgenic plants. Proc. Natl. Acad. Sci. USA (2001) 98(5):2899-2904.
9. SRIRAMAN R, BARDOR M, SACK M et al.: Recombinant anti-hCG antibodies retained in the endoplasmic reticulum of transformed plants lack core-xylose and core-aα(1,3)-rucose residues. Plant Biotechnol. J. (2004) 2(4):279-288.
10. DECKER E, RESKI R: The moss bioreactor. Curr. Opin. Plant Biol. (2004) 7(2):166-170.
11. YANO A, MAEDA F, TAKEKOSHI M: Transgenic tobacco cells producing the human monoclonal antibody to hepatitis B virus surface antigen. J. Med. Virol. (2004) 73(2):208-215.
12. BEASLEY PR, HWANG LY, STEVENS CE et al.: Efficacy of hepatitis B immune globulin for perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial. Hepatolagy (1983) 3(2):135-141.
13. MULLER R, GUBERNATIS G, PARLE M et al.: Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunization. Hepatology (1991) 13(1):90-96.
14. GALUN E, EREN R, SAFADI R et al.: Clinical evaluation (Phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatolagy (2002) 35(3):673-679.
15. KELLER MA, STIEHM ER: Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. (2000) 13(4):602-614.
16. PETERSON RK, ARNTZEN CJ: On risk and plant-based biopharmaceuticals. Trends Biotechnol. (2004) 22(2):64-66.
17. KAPUSCINSKI AR, GOODMAN RM, HANN SD et al.: Making 'safety first' a reality for biotechnology products. Nat. Biotechnol. (2003) 21(6):599-601.
18. MASCIA PN, FLAVELL RB: Safe and acceptable strategies for producing foreign molecules in plants. Curr. Opin. Plant Biology (2004) 7(2):189-195.
19. GUIDANCE FOR INDUSTRY: Drugs, biologics, and medical devices derived from bioengineered plants for use in humans and animals, draft guidance. Docket No. 02D-0324, CBER 2001 34. Fed. Reg. (2002) 67:57828-57829.
20. NO AUTHORS LISTED: Drugs in crops - the unpalatable truth. Nat. Biotechnol. (2004) 22(2):133.
21. STEWART CN JR, HALFHILL MD, WARWICK SI: Transgene introgression from genetically modified crops to their wild relatives. Nat. Rev. Genet. (2003) 4(10):806-817.
22. HINO A: Safety assessment and public concerns for genetically modified food products: the Japanese experience. Toxicol. Pathol. (2002) 30(1):126-128.
23. SMYTH S, PHILLIPS PW: Labeling to manage marketing of GM foods. Trends Biotechnol. (2003) 21(9):389-393.
24. RUTTAN VW: The transition to agricultural sustainability. Proc. Natl. Acad. Sci. USA (1999) 96(11):5960-5967.
25. KATE RW, PARRIS TM: Long-term trends and a sustainability transition. Proc. Natl. Acad. Sci. USA (2003) 100(14):8062-8067.
26. PILATE G, GUINEY E, HOLT K et al.: Field and pulping performances of transgenic trees with altered lignification. Nat. Biotechnol. (2002) 20(6):607-612.
27. YE X, AL-BABILI S, KLOTI A et al.: Engineering the provitamin A (β-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Science (2000) 287(5451):303-305.
28. RASKIN I, RIBNICKY DM, KOMARNYTSKY S et al.: Plants and human health in the twenty-first century. Trends Biotechnol. (2002) 20(12):522-531.
29. MA JK, DRAKE PM, CHRISTOU P: The production of recombinant pharmaceutical proteins in plants. Nat. Rev. Genet. (2003) 4(10):794-805.